A 52-Week Study of Dose-Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-injector

This open-label, single-arm, dose-blinded, 52-week, registration-phase study evaluated the efficacy and safety of subcutaneous testosterone enanthate auto-injector (SCTE-AI) administered weekly to men with hypogonadism.

Source: The Journal of Urology - October 5, 2018 Category: Urology & Nephrology Authors: Jed C. Kaminetsky, Andrew McCullough, Kathleen Hwang, Jonathan S. Jaffe, Christina Wang, Ronald S. Swerdloff Source Type: research